SCHEMBL31729157

SCHEMBL31729157

COc1cc(F)c(-c2ccc(F)c(Cl)c2F)c2ncnc(N)c12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE5A O76074 1/20 0.39
▸ EPHB4 P54760 3/20 0.38
▸ EGFR P00533 3/20 0.38
▸ ABL1 P00519 2/20 0.38
▸ HCK P08631 2/20 0.38
▸ SRC P12931 2/20 0.38
▸ KDR P35968 2/20 0.38
▸ PIK3CB P42338 2/20 0.38
▸ MTOR P42345 2/20 0.38
▸ PIK3CG P48736 2/20 0.38
▸ PRKDC P78527 2/20 0.38
▸ PI4KB Q9UBF8 2/20 0.38
▸ EIF2AK3 Q9NZJ5 9/20 0.38
▸ PIK3CD O00329 1/20 0.38
▸ PIK3CA P42336 1/20 0.38
▸ LRRK2 Q5S007 1/20 0.36
▸ KIT P10721 1/20 0.35
▸ CLK1 P49759 2/20 0.34
▸ FYN P06241 1/20 0.34
▸ ERBB2 P04626 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31728714 0.90 FYN (0.39) PDE5AEPHB4EGFRABL1HCK
SCHEMBL31728941 0.87 EIF2AK3 (0.39) PDE5AEPHB4EGFRABL1HCK
SCHEMBL31728213 0.84 EIF2AK3 (0.38) PDE5AEPHB4EGFRABL1HCK
SCHEMBL31728961 0.84 EGFR (0.38) EPHB4EGFRABL1HCKSRC
SCHEMBL31728591 0.82 EIF2AK3 (0.39) PDE5AEPHB4EGFRABL1HCK
SCHEMBL31728453 0.82 CLK1 (0.38) EPHB4EGFRABL1HCKSRC
SCHEMBL31728182 0.80 MET (0.35) EPHB4EGFRABL1HCKSRC
SCHEMBL31728084 0.80 MET (0.35) EPHB4EGFRABL1HCKSRC
SCHEMBL31727952 0.80 EIF2AK3 (0.42) PDE5AEPHB4EGFRABL1HCK
SCHEMBL31729265 0.79 MAP4K4 (0.43) PDE5AEPHB4EGFRABL1HCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025235874-A1 HETEROCYCLICS AS EGFR INHIBITORS SCHRÖDINGER, INC. (US) 2025-11-13 — — WO disclosed
Send feedback